Resource Center
Hard-earned insights that help drug manufacturers achieve their growth, compliance, and profitability objectives
Understanding the complexities of implementing a generic pharmaceutical company commercialization plan.
Understanding the complexities of implementing a generic pharmaceutical company commercialization plan.Seasoned pharma executives know that implementing a generic pharmaceutical company commercialization plan in the US market is a complex exercise in multi-tasking....
Understanding Baseline AMP Rules Can Help You Avoid Pricing Decision Disasters
Understanding Baseline AMP Rules Can Help You Avoid Pricing Decision DisastersWhat brand and generic drug manufacturers need to knowA lack of understanding respective to baseline Average Manufacturer Price (AMP) and how it can affect your Medicaid pricing can result...
Continued Emergence of Drug Price Disclosure Legislation – April 2020
Continued Emergence of Drug Price Disclosure LegislationTips for staying compliant with an accelerating trendStates Have Gotten Aggressive with Fines Against Pharma Companies for Price Reporting Noncompliance This paper, our third in a series that looks at the rising...
Avoiding Costly Government Pricing Mistakes
Avoiding Costly Government Pricing MistakesBasic steps pharmaceutical manufacturers should employ to avoid erroneous government pricing calculationsManaging Government Pricing (GP) computations can feel a bit like walking through a cave without a flashlight. Even an...
Continued Emergence of Drug Price Disclosure Legislation – January 2020
Continued Emergence of Drug Price Disclosure LegislationTips for staying compliant with an accelerating trendThe summer of 2019 saw an 86 percent increase in the number of states enacting pharmaceutical drug price disclosure laws. This paper, our second in a series...
Drug Price Disclosure Legislation – April 2019
Drug Price Disclosure LegislationFour steps to staying ahead and staying compliantMany states have moved to enact mandatory pharmaceutical price disclosure laws that would increase price transparency to address prescription drug costs (Fig. 1, pg. 3). In 2018, states...